Daniel S. Berman, MD, born on July 15, 1944

Affiliations

¹ Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA, USA. hschelbert@mednet.ucla.edu.

Heinrich R Schelbert et al. J Nucl Cardiol. 2021 Dec.

. 2021 Dec;28(6):2479-2482.

doi: 10.1007/s12350-021-02823-3. Epub 2021 Oct 19.

¹ Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA, USA. hschelbert@mednet.ucla.edu.

No abstract available

References

1. Roberts WC. Dean Towle Mason, MD: A conversation with the editor. Am J Cardiol 2002;90:1336‐67. - DOI
1. Garcia E, Maddahi J, Berman D, Waxman A. Space/time quantitation of thallium-201 myocardial scintigraphy. J Nucl Med 1981;22:309‐17. - PubMed
1. Ladenheim ML, Pollock BH, Rozanski A, Berman DS, Staniloff HM, Forrester JS, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol 1986;7:464‐71. - DOI
1. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900‐7. - DOI